This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markman, M. Articles by Bookman, M. A. Search for Related Content PubMed PubMed Citation Articles by Markman, M. Articles by Bookman, M. A.

Second-Line Treatment of Ovarian Cancer

^a The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA; ^b Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Correspondence: Michael A. Bookman, M.D., Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA. Telephone: 215-728-2987; Fax: 215-728-3877; e-mail: ma_bookman{at}fccc.edu

Patients with epithelial ovarian cancer are often diagnosed with advanced-stage disease. Although clinical complete remissions are obtained in the majority of patients through a combination of cytoreductive surgery and chemotherapy, relapse is common. A number of agents with diverse biologic mechanisms have been identified with activity in the setting of recurrent disease. Strategies for management of patients with recurrent disease, including classification, treatment goals, and therapeutic options will be reviewed.

Key Words. Chemotherapy • Epithelial ovarian cancer • Platinum • Resistance

This article has been cited by other articles:

				G. OSKAY-OZCELIK and J. SEHOULI Pros and Cons for Systemic Therapy in Recurrent Ovarian Cancer Anticancer Res, July 1, 2009; 29(7): 2831 - 2836. [Abstract] [Full Text] [PDF]

				Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, and S. ADACHI A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer Anticancer Res, May 1, 2009; 29(5): 1521 - 1526. [Abstract] [Full Text] [PDF]

				J. M. Saucier, J. Yu, A. Gaikwad, R. L. Coleman, J. K. Wolf, and J. A. Smith Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model Journal of Oncology Pharmacy Practice, March 1, 2007; 13(1): 39 - 45. [Abstract] [PDF]

				M. Markman Topotecan as Second-Line Therapy for Ovarian Cancer: Dosage Versus Toxicity Oncologist, October 1, 2005; 10(9): 695 - 697. [Abstract] [Full Text] [PDF]

				M. R. Raspollini, F. Castiglione, D. Rossi Degl'Innocenti, G. Amunni, A. Villanucci, F. Garbini, G. Baroni, and G. L. Taddei Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma Ann. Onc., April 1, 2005; 16(4): 590 - 596. [Abstract] [Full Text] [PDF]

				G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients Clin. Cancer Res., July 1, 2004; 10(13): 4420 - 4426. [Abstract] [Full Text] [PDF]

				M. B. Flick, D. O'Malley, T. Rutherford, S. Rodov, M. Kamsteeg, X.-Y. Hao, P. Schwartz, B. M. Kacinski, and G. Mor Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients Reproductive Sciences, May 1, 2004; 11(4): 252 - 259. [Abstract] [PDF]

				M. R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G. L. Taddei c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study Ann. Onc., April 1, 2004; 15(4): 594 - 597. [Abstract] [Full Text] [PDF]

				M. Markman Ethical Conflict in Providing Informed Consent for Clinical Trials: A Problematic Example from the Gynecologic Cancer Research Community Oncologist, February 1, 2004; 9(1): 3 - 7. [Abstract] [Full Text] [PDF]

				L. Zhang, J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer N. Engl. J. Med., January 16, 2003; 348(3): 203 - 213. [Abstract] [Full Text] [PDF]

				D. C. Bodurka, C. Levenback, J. K. Wolf, J. Gano, J. T. Wharton, J. J. Kavanagh, and D. M. Gershenson Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer J. Clin. Oncol., January 15, 2003; 21(2): 291 - 297. [Abstract] [Full Text] [PDF]

				S. H. Wei, C.-M. Chen, G. Strathdee, J. Harnsomburana, C.-R. Shyu, F. Rahmatpanah, H. Shi, S.-W. Ng, P. S. Yan, K. P. Nephew, et al. Methylation Microarray Analysis of Late-Stage Ovarian Carcinomas Distinguishes Progression-free Survival in Patients and Identifies Candidate Epigenetic Markers Clin. Cancer Res., July 1, 2002; 8(7): 2246 - 2252. [Abstract] [Full Text] [PDF]

				M. Markman, A. Kennedy, K. Webster, G. Peterson, B. Kulp, and J. Belinson Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum J. Clin. Oncol., April 1, 2001; 19(7): 1901 - 1905. [Abstract] [Full Text] [PDF]